ADMA News and Press, ADMA Biologics Inc From 04/16/24

2024-04-16 21:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-04-03 06:00:00 ET Summary ADMA Biologics' stock has seen a significant rally, fueled by growth in plasma-derived biologics and improved financial health. Recent earnings highlight revenue growth, operational efficiencies, and a shift towards profitability, with notable progre...

FDA Approval Provides for Room Temperature (25°C) Storage Conditions for up to 4 Weeks at Any Point During the 36-Month Approved Shelf Life Extends the Prior Room Temperature Storage Allowance for the Full 36-months for ASCENIV and BIVIGAM Provides for Improved Inventory Ma...

RAMSEY, N.J. and BOCA RATON, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today anno...

RAMSEY, N.J. and BOCA RATON, Fla., Feb. 28, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announ...

4Q 2023 Total Revenue of $73.9 Million; FY 2023 Total Revenue of $258.2 Million 4Q 2023 Adjusted EBITDA ( 1 ) of $18.6 Million; FY 2023 Adjusted EBITDA of $40.3 Million 4Q 2023 Adjusted Net Income ( 2 ) of $8.5 Million; FY ...

SilverBow Resorces Inc. (SBOW) is expected to report $2.36 for Q4 2023 FAT Brands Inc. Class B Common Stock (FATBB) is expected to report for quarter end 2023-12-31 Ecovyst Inc. (ECVT) is expected to report $0.2 for Q4 2023 MYR Group Inc. (MYRG) is expected to report $1.41 for Q4 2023...

RAMSEY, N.J. and BOCA RATON, Fla., Feb. 21, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today annou...

ADMAlytics Combines Generative AI and Machine Learning to Optimize Production Processes ADMA Successfully Utilized ADMAlytics’ New Capabilities for the First Time to Automate and Realize Efficiency Improvements for Commercial Production Plasma Pooling Broader Implementati...

2024-01-19 07:51:35 ET Summary ADMA Biologics enters 2024 on quite a roll and the stock should continue to do well going forward. The company has recently completed the build of its plasma collection network, turned the corner on profitability, and redid its credit facility in a p...